Intelligence Β· Clinical Pipeline

HALOZYME THERAPEUTICS Pipeline

All ClinicalTrials.gov programs at HALOZYME THERAPEUTICS β€” phase, modality, and trial IDs.

Programs
16

Quick answer

HALOZYME THERAPEUTICS has 16 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. 5-Fluorouracil (5-FU)

    HALOZYME THERAPEUTICS, INC.

    Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

    phase 2 small molecule completed

    1 trial
  2. Atezolizumab

    HALOZYME THERAPEUTICS, INC.

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule terminated

    1 trial
  3. Axumin PET/CT

    HALOZYME THERAPEUTICS, INC.

    Prostate Cancer

    phase 2 small molecule completed

    1 trial
  4. CINRYZE with rHuPH20

    HALOZYME THERAPEUTICS, INC.

    Hereditary Angioedema

    phase 2 mab completed

    1 trial
  5. Eribulin mesylate

    HALOZYME THERAPEUTICS, INC.

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial
  6. Gemcitabine

    HALOZYME THERAPEUTICS, INC.

    Stage IV Pancreatic Cancer

    phase 2 small molecule completed

    1 trial
  7. Humalog

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial
  8. Humalog

    HALOZYME THERAPEUTICS, INC.

    Type 1 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial
  9. Insulin lispro

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    2 trials
  10. Insulin lispro

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus, Type II

    phase 2 small molecule completed

    1 trial
  11. Mitomycin C

    HALOZYME THERAPEUTICS, INC.

    Bladder Cancer

    phase 2 small molecule completed

    1 trial
  12. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    Metastatic Pancreatic Adenocarcinoma

    phase 2 small molecule completed

    1 trial
  13. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial
  14. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial
  15. Pegvorhyaluronidase alfa

    HALOZYME THERAPEUTICS, INC.

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule terminated

    1 trial
  16. rHuPH20

    HALOZYME THERAPEUTICS, INC.

    Dermatitis, Allergic Contact

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does HALOZYME THERAPEUTICS have?

16 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources Β· All pipeline programs